Table 1 Patient demographics and baseline clinical characteristics in the primary and validation cohorts
Characteristic | Primary cohort (85) No. (%) | Validation cohort (77) No. (%) | P Value | ||||
|---|---|---|---|---|---|---|---|
All patients(85) | non-DCR (47) | DCR (38) | All patients(77) | non-DCR (30) | DCR (47) | ||
Age, years, n (%) | |||||||
≥ 48 | 45(52.9%) | 31(66.0%) | 14(36.8%) | 51(66.2%) | 18(60.0%) | 33(70.2%) | 0.086 |
< 48 | 40(47.1%) | 16(34.0%) | 24(63.2%) | 26(33.8%) | 12(40.0%) | 14(29.8%) | |
Sex, n (%) | |||||||
Male | 55(64.7%) | 30(63.8%) | 25(65.8%) | 51(66.2%) | 18(60.0%) | 33(70.2%) | 0.838 |
Female | 30(35.3%) | 17(36.2%) | 13(34.2%) | 26(33.8%) | 12(40.0%) | 14(29.8%) | |
ECOG score, n (%) | |||||||
0 | 25(30.1%) | 13(27.7%) | 12(31.6%) | 31(40.3%) | 9(30.0%) | 22(46.8%) | 0.179 |
1 | 58(69.9%) | 34(72.3%) | 26(68.4%) | 46(59.7%) | 21(70.0%) | 25(53.2%) | |
Smoke, n (%) | |||||||
Yes | 29(34.1%) | 19(40.4%) | 10(26.3%) | 21(27.3%) | 10(33.3%) | 11(23.4%) | 0.346 |
No | 56(65.9%) | 28(59.6%) | 28(73.7%) | 56(72.7%) | 20(66.7%) | 36(76.6%) | |
Alcohol, n (%) | |||||||
Yes | 13(15.3%) | 7(14.9%) | 6(15.8%) | 15(19.5%) | 8(26.7%) | 7(14.9%) | 0.482 |
No | 72(84.7%) | 40(85.1%) | 32(84.2%) | 62(80.5%) | 22(73.3%) | 40(85.1%) | |
Tumor classification, n (%) | |||||||
Lung cancer | 12(14.1%) | 9(9.1%) | 3(7.9%) | 21(27.3%) | 7(23.3%) | 14(29.8%) | 0.068 |
Nasopharyngeal carcinoma | 37(43.5%) | 20(42.6%) | 17(47.7%) | 24(31.2%) | 4(13.3%) | 20(42.6%) | |
Gastrointestinal tumors | 22(25.9%) | 13(27.7%) | 9(23.7%) | 14(18.2%) | 7(23.3%) | 7(14.9%) | |
Melanoma | 14(16.5%) | 5(10.6%) | 9(23.7%) | 18(23.4%) | 12(40.0%) | 6(12.8%) | |
Stage, n (%) | |||||||
III | 33(38.8%) | 16(34.0%) | 17(44.7%) | 24(31.2%) | 5(16.7%) | 19(40.4%) | 0.308 |
IV | 52(61.2%) | 31(66.0%) | 21(55.3%) | 53(68.8%) | 25(83.3%) | 28(59.6%) | |
Distant metastasis sites, n (%) | |||||||
Lung | 18(23.7%) | 10(22.7%) | 8(25.0%) | 19(27.1%) | 13(34.2%) | 6(18.8%) | 0.230 |
Liver | 17(22.4%) | 9(20.5%) | 8(25.0%) | 9(12.9%) | 2(5.3%) | 7(21.9%) | |
Bone | 19(25.0%) | 12(27.3%) | 7(21.9%) | 15(21.4%) | 10(26.3%) | 5(15.6%) | |
Other | 22(28.9%) | 13(29.5%) | 9(28.1%) | 27(38.6%) | 13(34.2%) | 14(43.8%) | |
No. of metastatic sites, n (%) | |||||||
< 2 | 64(75.3%) | 33(70.2%) | 31(81.6%) | 52(67.5%) | 16(53.3%) | 37(76.6%) | 0.274 |
≥ 2 | 21(4.7%) | 14(29.8%) | 7(18.4%) | 25(32.5%) | 14(46.7%) | 11(23.4%) | |
Prior therapy, n (%) | |||||||
Yes | 71(83.5%) | 40(85.1%) | 31(81.6%) | 62(80.5%) | 23(23.3%) | 39(83.0%) | 0.618 |
No | 14(16.5%) | 7(14.9%) | 7(18.4%) | 15(19.5%) | 7(76.7%) | 8(17.0%) | |